Influence of everolimus-based treatment on circulating regulatory T cells after liver transplantation: Comparative study with tacrolimus-based therapy.

Barjon, Clément;Dahlqvist, Géraldine;Ghazal, Khaldoun;Saliba, Faouzi;Conti, Filomena;et.al.
(2021) Clinics and Research in Hepatology and Gastroenterology — Vol. 45, n° 5, p. 101559 [1-7] (2021)

Files

2020_Barjon_Clin_Res_Hepatol_Gastroenterol.pdf
  • Open Access
  • Adobe PDF
  • 756.01 KB
Download

Details

Authors
  • Barjon, ClémentUCLouvain
    Author
  • Dahlqvist, GéraldineUCLouvain
    Author
  • Ghazal, Khaldoun
    Author
  • Saliba, Faouzi
    Author
  • Conti, Filomena
    Author
Show more
Abstract
Liver transplantation remains the only treatment for terminal liver diseases. However, immunosuppressive drugs required for allograft acceptance are toxic and may be responsible for severe side effects. Modulating the immune system to induce tolerance is a promising approach to reduce immunosuppressive regimen. More particularly, promoting natural CD4 CD25 FoxP3 Tregs could be crucial in achieving tolerance. Contrary to calcineurin inhibitors, reports indicate that mTOR inhibitors may have a positive impact on Tregs. Here we present the first randomized prospective clinical study where Tregs levels from liver transplanted patients receiving either tacrolimus or everolimus were monitored for 6 months, starting from the day of transplantation. A total of 30 patients from four centers were monitored. Blood samples were obtained at day 0, day 14, one month, three months and six months post-transplantation. Flow-cytometry immunophenotyping of Tregs (CD4 CD25 CD127 FoxP3) and functional assays with Tregs were performed to assess their immunosuppressive capacity. Levels of Tregs were significantly reduced after one month of standard tacrolimus-based immunosuppressive regimen (p < 0.05). Four months after conversion, levels of Tregs from patients treated with everolimus was significantly higher than patients under tacrolimus (p < 0.02). Functional assays demonstrated that Tregs conserved their capacity to suppress the proliferation of activated PBMC.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Barjon, C., Dahlqvist, G., Ghazal, K., Saliba, F., Durand, F., Duvoux, C., Aoudjehane, L., & Conti, F. (2021). Influence of everolimus-based treatment on circulating regulatory T cells after liver transplantation: Comparative study with tacrolimus-based therapy. Clinics and Research in Hepatology and Gastroenterology, 45(5), 101559 [1-7]. https://doi.org/10.1016/j.clinre.2020.10.004 (Original work published 2021)